"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Niforatos JD, Pescatore RM. Financial relationships with industry among guideline authors for the management of acute ischemic stroke. Am J Emerg Med. 2019 05; 37(5):921-923.
-
Tollman P, Panier V, Dosik D, Biondi P, Cuss F. Organizational effectiveness: a key to R&D productivity. Nat Rev Drug Discov. 2016 07; 15(7):441-2.
-
Hilferty D, Herman B. There's a risk that value-based payment 'is more lip service than the real thing'. Mod Healthc. 2015 Nov 09; 45(45):34-5.
-
McGregor AJ, Barr H, Greenberg MR, Safdar B, Wildgoose P, Wright DW, Hollander JE. Gender-specific Regulatory Challenges to Product Approval: a panel discussion. Acad Emerg Med. 2014 Dec; 21(12):1334-8.
-
Krane NA, Sataloff RT. Understanding the regulation of pharmaceutical drug promotion [Editorial]. Ear Nose Throat J. 2014 Dec; 93(12):486-8.
-
Haller JA. Strengthened ties between industry and academia are historical, productive, and crucial. Surv Ophthalmol. 2014 May-Jun; 59(3):348-53.
-
Skolnik N. Don't restrict funding from drug companies for doctors' education. BMJ. 2013 Nov 08; 347:f6452.
-
Stefanacci RG, Guerin S. Why medication adherence matters to patients, payers, providers. Manag Care. 2013 Jan; 22(1):37-9.
-
Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012 Apr; 30(4):257-70.
-
Cottens S, Eaton M, Fuhr J, Geary S, Johnson DS, Li G, Raveglia L, Robertson GM, Westwell A. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Future Med Chem. 2011 Nov; 3(15):1863-72.